Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This phase 2a study will involve enrolment of men presenting with progression of biopsy
proven prostate cancer who require imaging for staging/re-staging of their disease. The
participants enrolled will be further sub-stratified into two groups; one group of men with
hormone-sensitive disease (cohort A), and a second group of men with castrate-resistant
disease being considered for 177Lu-PSMA-617 therapy (Cohort B).